DHT is the villain, but scalp perfusion is the lever most hair stacks quietly rely on. Here's what circulation actually does for follicles, which vasodilators pull their weight, and where the theory gets oversold.
Every hair protocol eventually runs into the same observation: two guys on identical finasteride doses can have wildly different outcomes, and the guy who added minoxidil, microneedling, or low-dose tadalafil usually wins. That pattern has pushed a chunk of the community toward a bigger claim — that local bloodflow, not just DHT mitigation, is the hidden variable behind the best regrowth stacks. The claim is partially right, partially overstated, and worth picking apart before you start stacking vasodilators on top of each other.
Terminal follicles are metabolically expensive. They run a continuous anagen phase for years, pumping out keratin 24/7, and the dermal papilla sits at the bottom of a dense capillary plexus that has to deliver oxygen, glucose, amino acids, and signaling factors on demand. When that plexus regresses — and it does regress in androgenetic alopecia, well before the follicle miniaturizes visibly — the follicle downshifts. Shorter anagen, thinner shafts, more telogen, eventually vellus.
The DHT story and the perfusion story aren't competing theories. DHT binding at the androgen receptor in genetically susceptible follicles triggers perifollicular inflammation and microvascular rarefaction. The capillary loss is downstream of DHT, but once it happens it becomes its own problem — and restoring flow can partially rescue follicles that haven't fully miniaturized. This is why pure anti-androgen monotherapy tends to stabilize rather than regrow, while adding a perfusion agent often recovers density.
"I am starting to believe that bloodflow is the reason for hair loss... It is a generality based on dht promoting hair growing not on the scalp." — r/tressless thread
The observation the OP is circling — body hair thrives under high DHT while scalp hair dies — is real, and perfusion differences between androgen-sensitive and androgen-insensitive skin are part of the explanation. But "bloodflow is the reason" overshoots. Without the AR-mediated trigger, the capillary rarefaction doesn't start. Flow is the lever, not the cause.
Not every "bloodflow agent" hits the scalp the same way. A quick map of what's on the table:
| Agent | Mechanism | Evidence for hair |
|---|---|---|
| Minoxidil (topical) | K+ channel opener, sulfotransferase-dependent, pro-angiogenic via VEGF | Strongest; FDA-approved; decades of data |
| Minoxidil (oral, 1.25-5mg) | Same, systemic | Growing evidence, works in topical non-responders |
| Tadalafil (2.5-5mg daily) | PDE5 inhibition, NO-mediated vasodilation | Suggestive; small trials and strong anecdote |
| Microneedling (1.0-1.5mm) | Mechanical wound response, VEGF, Wnt/beta-catenin | Solid; synergizes with minoxidil in trials |
| GHK-Cu (topical) | Angiogenic copper peptide, perifollicular remodeling | Modest; useful adjunct |
| Exercise / scalp massage | Shear-stress mediated NO | Weakest on its own, basically free |
Minoxidil is the anchor. It's the only one with unambiguous long-term regrowth data, and the oral route has quietly become the community default for anyone whose scalp doesn't tolerate the topical or who just doesn't want to apply a liquid twice a day. The pro-angiogenic effect via VEGF is arguably more important than the acute vasodilation — it's why it takes 3-6 months to see results instead of 3-6 days.
Tadalafil is the interesting one. Daily 2.5-5mg is already popular among physique-focused users for pump, blood pressure control on cycle, and erectile function, and the scalp benefit shows up as a bonus. A handful of small trials suggest improved density, and the mechanism (sustained NO-mediated perfusion) is plausible. Hard contraindication: do not combine PDE5 inhibitors with nitrates or nitric-oxide donor recreational drugs — the hypotension can be severe.
A few places the argument runs ahead of the evidence:
For someone already on a 5-AR inhibitor or topical AR antagonist and looking to actually drive regrowth:
If you're running AAS, the stack matters more, not less. Exogenous androgens accelerate miniaturization in susceptible follicles, and blood pressure tends to drift up, which is its own hit to scalp perfusion. Keeping BP in range with a real antihypertensive (telmisartan is the community favorite) is arguably a bloodflow intervention in its own right.
Photographs under consistent lighting, same angle, same hairstyle, every 90 days. Not daily mirror checks. The first 8-12 weeks on any new perfusion agent usually involves a shed as follicles synchronize out of telogen — that's a signal the drug is doing something, not evidence it's failing. Judge density at month 6 and trajectory at month 12.
Bloodflow isn't the secret cause of hair loss, but it is the single biggest lever most successful regrowth stacks pull — and the reason minoxidil still anchors every serious protocol decades after approval. Lock down the AR side first, add minoxidil, add microneedling, and consider tadalafil if it fits the rest of your protocol. Stacking a fourth vasodilator on top of that is almost always wasted effort.
Powered by BTST